Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CARVEDILOL | 12.5MG | TABLET | Resolved | 2017-11-28 | 2018-05-27 | 30992 |
| APO-CARVEDILOL | 12.5MG | TABLET | Resolved | 2023-09-01 | 2023-11-17 | 203554 |
| APO-CEFACLOR | 250MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19036 |
| APO-CEFACLOR | 500MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19039 |
| APO-CEFACLOR | 125MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19066 |
| APO-CEFACLOR | 250MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19069 |
| APO-CEFACLOR | 375MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19072 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-07-25 | 2024-08-09 | 233706 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-09-12 | 2024-10-11 | 237372 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-11-14 | 2024-12-13 | 243086 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2019-07-12 | 2019-11-25 | 89155 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2023-04-21 | 2024-03-08 | 190008 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2025-01-16 | 2025-02-28 | 247862 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2021-07-23 | 2021-10-12 | 142973 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2017-04-17 | 2017-04-25 | 7102 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2022-11-20 | 2022-12-23 | 175327 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2022-04-08 | 2022-08-24 | 158348 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2019-03-27 | 2019-03-29 | 79574 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-07-31 | 2019-08-02 | 90341 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-12-05 | 2020-02-18 | 100265 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
| APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
| APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
| APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
| APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
| APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
| APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
| APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
| APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
| APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
| APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
| APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
| APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |